Combinib 250 Mg

Name: Combinib 250 Mg
Brand: Maheshwari Medical Agency
Price: 5000 INR
Availability: InStock

Price 5000 INR/ Pack

Get a Price/Quote

MOQ : 1 Pack

Combinib 250 Mg Specification

Dosage Form
Tablet

Brand Name
Combinib 250 Mg

Indication
Indicated for treatment of advanced or metastatic breast cancer

Salt Composition
Lapatinib Ditosylate Monohydrate 250 mg

Pacakaging (Quantity Per Box)
30 tablets

Origin of Medicine
India

Life Span
2 years from date of manufacture

Packaging Type
Box

Drug Type
Allopathic

Ingredients
Lapatinib Tablets IP

Physical Form
Tablet

Function
Anticancer / Used in HER2-positive breast cancer

Recommended For
Used in treatment of breast cancer

Dosage
As directed by physician

Dosage Guidelines
Take whole with water, do not crush or chew

Suitable For
Adults

Quantity
30 tablets per box

Storage Instructions
Store below 30C, protect from moisture and light

Therapeutic Class
Antineoplastic Agents

MRP
As per strip/box, varies regionally

Prescription Required
Yes

Marketed By
Cipla Ltd.

HSN Code
3004

Color
Yellow

Approval
Approved by regulatory authorities in India

Side Effects
May include diarrhea, nausea, rash, and tiredness

Route of Administration
Oral

Shape
Oval

Combinib 250 Mg Trade Information

Minimum Order Quantity
1 Pack

Supply Ability
1000 Packs Per Month

Delivery Time
7 Days

About Combinib 250 Mg

Discover the celebrated Combinib 250 Mg, a peerless treatment for HER2-positive breast cancer. Engineered for adults and marketed by Cipla Ltd., this marvelous oral tablet contains Lapatinib Ditosylate Monohydrate, known for its antineoplastic properties. Pick yours today-each box houses 30 vibrant yellow, oval-shaped tablets, ensuring convenience and consistency in your regimen. Indicated for advanced or metastatic breast cancer, Combinib is approved by regulatory authorities in India. Shop now and get unrivaled quality, storage superiority, and a globally trusted brand, all tailored for optimal dosage and administration. Prescription required. Get yours now!

Application, User Profile & Site of Action

Combinib 250 Mg is primarily used in the management of advanced or metastatic HER2-positive breast cancer. Specifically recommended for adults, its action is delivered orally, making it suitable for those who prefer tablet-based therapies. The principal site of action is systemic, targeting cancer cells throughout the body. Its celebrated efficacy provides essential support to oncologists and patients aiming for comprehensive cancer care in a trusted format.

Packaging, Certification, & Export Details

Each box of Combinib 250 Mg contains a secure pack of 30 tablets, designed for the utmost protection against moisture and light, ensuring consistency during goods transport. With approval by regulatory authorities in India, the product rate and supply fulfill stringent quality guidelines. Order processing is streamlined for both local and international markets, supporting distributors, suppliers, and traders. The robust packaging and authentic certifications make it suitable for the global pharmaceutical marketplace.

FAQ's of Combinib 250 Mg:

Q: How should Combinib 250 Mg be taken for optimum benefit?

A: Combinib 250 Mg should be taken orally as prescribed by your physician, swallowed whole with water. It is recommended not to crush or chew the tablet. Always follow the dosage instructions provided by your healthcare provider for best results.

Q: What are the common side effects of Combinib 250 Mg?

A: Possible side effects may include diarrhea, nausea, rash, and tiredness. If you encounter persistent or severe reactions, consult your medical professional promptly to discuss management or alternative options.

Q: When is Combinib 250 Mg typically recommended?

A: Combinib 250 Mg is indicated for the treatment of advanced or metastatic HER2-positive breast cancer in adults. It is used under physician supervision, especially in scenarios where other treatments have shown limited effect.

Q: Where is Combinib 250 Mg approved and manufactured?

A: Combinib 250 Mg is approved by regulatory authorities in India and manufactured by Cipla Ltd. With strict adherence to Indian pharmaceutical standards, its distribution covers both domestic and selected global markets.

Q: What should you consider during storage and handling of Combinib 250 Mg?

A: The tablets should be stored in a cool, dry place below 30C, protected from moisture and light. Adhering to these storage instructions helps preserve the tablet's effectiveness and longevity, ensuring optimal treatment outcomes.

Tell us about your requirement